Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MORF Morphic (MORF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends About Morphic Stock (NASDAQ:MORF) 30 days 90 days 365 days Advanced Chart Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get Morphic alerts:Sign Up Key Stats Today's Range$56.99▼$56.9950-Day Range$55.74▼$56.9952-Week Range$19.34▼$57.00Volume400 shsAverage Volume1.27 million shsMarket Capitalization$2.85 billionP/E RatioN/ADividend YieldN/APrice Target$57.00Consensus RatingHold Company OverviewMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More… Morphic Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks15th Percentile Overall ScoreMORF MarketRank™: Morphic scored higher than 15% of companies evaluated by MarketBeat, and ranked 883rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingMorphic has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMorphic has received no research coverage in the past 90 days.Read more about Morphic's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Morphic are expected to decrease in the coming year, from ($4.07) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Morphic is -16.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Morphic is -16.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphic has a P/B Ratio of 4.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MORF. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMorphic does not currently pay a dividend.Dividend GrowthMorphic does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.57 Short InterestThere is no current short interest data available for MORF. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for MORF on MarketBeat in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Morphic insiders have not sold or bought any company stock.Percentage Held by Insiders25.60% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.25% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Morphic's insider trading history. Receive MORF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter. Email Address MORF Stock News HeadlinesMorphic Ethical Equities Fund LimitedOctober 25, 2024 | afr.comEli Lilly acquires Morphic in IBD portfolio expansionAugust 19, 2024 | finance.yahoo.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.December 22, 2024 | Insiders Exposed (Ad)MORF Jan 2025 25.000 put (MORF250117P00025000)August 17, 2024 | finance.yahoo.comLilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel DiseaseAugust 16, 2024 | prnewswire.comCalling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesAugust 8, 2024 | globenewswire.comMorphic Holding (MORF) Earnings Dates & ReportsAugust 6, 2024 | investing.comCalling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your LossesAugust 2, 2024 | globenewswire.comSee More Headlines MORF Stock Analysis - Frequently Asked Questions How were Morphic's earnings last quarter? Morphic Holding, Inc. (NASDAQ:MORF) issued its earnings results on Thursday, July, 25th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.96) by $0.19. When did Morphic IPO? Morphic (MORF) raised $75 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO. What other stocks do shareholders of Morphic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Morphic investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), SPDR S&P 500 ETF Trust (SPY), Advanced Micro Devices (AMD), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META) and Tesla (TSLA). Company Calendar Last Earnings7/25/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MORF CUSIPN/A CIK1679363 Webwww.morphictx.com Phone(781) 996-0955FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$57.00 High Stock Price Target$57.00 Low Stock Price Target$57.00 Potential Upside/Downside+0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,100,000.00 Net MarginsN/A Pretax Margin-29,119.96% Return on Equity-26.62% Return on Assets-25.74% Debt Debt-to-Equity RatioN/A Current Ratio24.13 Quick Ratio24.13 Sales & Book Value Annual Sales$520,000.00 Price / Sales5,490.11 Cash FlowN/A Price / Cash FlowN/A Book Value$12.31 per share Price / Book4.63Miscellaneous Outstanding Shares50,094,000Free Float37,270,000Market Cap$2.85 billion OptionableOptionable Beta1.49 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:MORF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our Partners⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Morphic Holding, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Morphic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
